TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
As previously announced by TESARO,Inc. (the “Company”), on October23, 2017, Edward C. English submitted his resignation as principal accounting officer of the Company. Mr.English will continue to serve until the effective date of his resignation on November24, 2017. On November9, 2017, the Board of Directors of the Company appointed Timothy R. Pearson, the Company’s Executive Vice President and Chief Financial Officer, to serve as the Company’s principal accounting officer, effective November25, 2017, until a successor is appointed.
About TESARO,Inc. (NASDAQ:TSRO) TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.